IDH2 and astrocytoma (excluding glioblastoma): Additionally, the majority of IDH-mutant astrocytomas are characterized by TP53 mutations, often coupled with ATRX loss in IDH-mutant gliomas, signal genomic instability and are generally predictive of better outcomes (43, 44).